CME
Latest Episodes
Advances in the Care of Patients with MSI-H/dMMR or HER2+ Colorectal Cancers
Host: Aparna R. Parikh, MD Guest: Dustin Deming, MD Guest: Scott Kopetz, MD, PhD In this chapterized panel discussion, Drs. Aparna Parikh, Dustin Deming, and Scott Kopetz take us through NCCN recommended guidelines and best practices for identify
Evaluating Your Current Options in the Treatment of NSCLC with METex14 Skipping Mutations
Host: Paul Paik, MD Guest: Catherine Shu, MD Take a deep dive into current and ongoing clinical trials related to MET inhibitors and discover the key distinctions between these agents, such as dosing differences. Our experts also have recommendatio
Patient-Centered Discussions and Shared Decision-Making in the Management of NSCLC with METex14 Skipping Mutations
Host: Jyoti D. Patel, MD, FASCO Join us as Dr. Jyoti Patel illustrates her approach to treating a 75-year-old patient who was recently diagnosed with stage IV NSCLC harboring a MET exon 14 skipping mutationthen put these tips to use in your own prac
Retina Clinic: Emerging Treatment Options in Diabetic Retinopathy
Host: Roger A. Goldberg, MD Guest: Peter A. Campochiaro, MD Can we apply the new, more durable treatments in diabetic macular edema and neovascular age-related macular degeneration to the treatment of our patients with diabetic retinopathy? Join Dr
Why ICIs Have Revolutionized Cancer Care
Guest: Patrick Forde, MD Guest: Jess Garca-Foncillas, MD, PHD Immune checkpoint inhibitors, or ICIs, have improved the prognosis for patients with many different types of cancer. Drs. Forde and Garca-Foncillas outline current biomarkers and the
Heart Failure Grand Rounds: 3 Things You Need to Know About Cardiac Contractility Modulation
Host: Javed Butler, MD, MBA, MPH Guest: William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPE Cardiac contractility modulation (CCM) is a novel, approved, implantable therapy that significantly improves heart failure symptoms, exercise tolerance, a
Treatment of CLL/SLL with BTKis: Whole Patient Approaches
Host: Lindsey Roeker, MD The disease continuum for chronic lymphocytic leukemia (CLL) has rapidly evolved to include non-chemotherapy-based regimens that disrupt B cell receptor signaling. The increased availability of active treatment regimens along
Closing Arguments
Guest: Richard Krasuski, MD Guest: Jamil A. Aboulhosn, MD Guest: Joseph Kay, MD tbd
Defense’s Arguments
Guest: Joseph Kay, MD Guest: Wayne J. Franklin, MD, FACC Guest: Richard Krasuski, MD Guest: Jamil A. Aboulhosn, MD tbd
Prosecution’s Arguments
Guest: Richard Krasuski, MD Guest: Jamil A. Aboulhosn, MD Guest: Alexander Opotowsky, MD, MMSc Guest: Joseph Kay, MD tbd